Company intelligence / Profile preview

Pluryn

Haifa, Israel

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Pluri’s lead candidates include PLX-PAD and PLX-R18. PLX-PAD has been evaluated in Phase II studies for muscle injury post-surgery and other ischemic conditions. PLX-R18 has been tested in Phase I for hematopoietic recovery following radiation exposure. The company also develops an allogeneic MAIT cell immunotherapy platform targeting solid tumors, currently at the preclinical stage. No products are yet approved or commercialized as of June 2025.

Therapeutic areas: PulmonologyHematologyCardiovascularOncologyRheumatologyWomen's Health
Modalities: Cell therapyAllogeneic cell therapyImmunotherapy (MAIT cell platform)Biologic (placental-derived cells)Small molecule (for cultivated meat/food-tech applications)
Industry: Biotech

Partnerships

Bar-Ilan University collaboration on cancer immunotherapyvarious pharmaceutical/research institution collaborations not individually named in public sources

Beyond the preview

Go deeper on Pluryn.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pluryn.

Explore the full profile